Novartis therapy for infant muscle-wasting disease — potentially carrying a record $2 million price tag — is about to hit market

A new treatment for an infant muscle-wasting disease is about to go on sale at a potential cost of $2 million, a record price tag likely to fuel the continuing scrutiny of how companies price their drugs and how insurers pay for them.